Shots: Why It Matters? IDEXX is extending its Cancer Dx platform into the UK, giving vets a blood-based panel that can be added to wellness profiles and delivers lymphoma results in 3–5 days with 79% sensitivity and 99% specificity. With real-world use in roughly 6,...
Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
